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Abstract
I have been invited to summarize my career with an emphasis on the time I spent in the laboratory of Prof ChristopherM.Dobson,
who sadly passed away on September 8th 2019, and to describe his role as a mentor. I accepted this slightly unusual request as it
constitutes a unique way for me to express my deep gratitude and admiration for Chris.
Early life in France and post-graduate study
in Japan
After graduating from my local high school in 1988 in the
southeast of France (Romans sur Isère), I spent 2 years of
study gaining a technical diploma in Biochemistry from
Grenoble (Lycée Louise Michel, 1988–1990) before being
admitted to the Ecole Nationale Supérieure des Industries
Agroalimentaires (ENSIA, Massy, France) where I trained as
an industrial engineer in food science (1991–1994). During
this time, I became interested in the use of high hydrostatic
pressure as an alternative technique to heat treatment for san-
itizing and texturizing food whilst better preserving its nutri-
tive value, original colour and flavour. This method of food
processing was pioneered in the mid-1980s by Prof. Rikimaru
Hayashi (Head of Biomacromolecular Chemistry in the
Department of Life Sciences at the University of Kyoto,
Japan) and it was viewed as an extremely promising one by
many European food companies and research groups. After
working for a couple of years as a high school biology teacher,
I earned a Monbusho scholarship to carry out a DSc in the
Hayashi group in Japan (1996–1999). My studies initially
focused on the textural properties of gels generated upon sub-
jecting proteins to high hydrostatic pressure and low temper-
atures. After 1 year, I accumulated enough data to publish a
paper on that project. I then decided to shift to a more funda-
mental topic, and I dedicated the final part of my PhD studies
to analysing the mechanism of pressure-induced cold denatur-
ation of carboxypeptidase Y, a protease from yeast (also dis-
covered by R. Hayashi). This new orientation was determinant
for my career, and without it, I most likely would never have
met Chris! I enjoyedmyDSc research with Hayashi-sensei; he
was a very inspirational and motivational supervisor. He al-
ways encouraged his students to participate in international
meetings and visit laboratories abroad to learn new tech-
niques. I thus spent a few weeks in the laboratory of Prof.
Claude Balny at INSERM in Montpellier (France) and in the
laboratory of Prof. PatrickMasson at Centre de Recherches du
Service de Santé des Armées (La tronche, France) in order to
carry out stopped-flow and electrophoresis experiments under
high pressure, respectively. With strong encouragement from
Prof. Hayashi, I published seven papers during my DSc in-
cluding two review articles and three conference proceedings
(e.g. Dumoulin et al. 1998; Dumoulin and Hayashi 1998).
Hayashi sensei was also keen to introduce his students to
many aspects of Japanese culture such as Noh theatres, the
local famous onsen (hot natural baths) and traditional restau-
rants. I retain great memories of these moments.
A postdoctoral fellowship in Belgium
After Japan, I moved to the University of Liège (Belgium) to
carry out postdoctoral work in the group of Dr. AndréMatagne,
himself a former postdoctoral fellow of Chris Dobson 1993–
1995, at the Center of Protein Engineering (CIP). My 2-year
position was funded by a European biotechnology network
aimed at investigating the stability and folding properties of a
set of VHHs. VHHs are the antigen binding domains of the so
called camelid heavy-chains antibodies (HcAb) which are de-
void of light chains. HcAb had been discovered in the group of
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R. Hammers at the Vrije Universiteit Brussel (VUB, Belgiun) a
few years earlier (Hamers-Casterman et al. 1993). This network
involved Prof. Lode Wyns and Prof. Serge Muyldermans from
the VUB who had generated VHHs against a range of proteins
including human lysozyme. Of interest to this story is that the
collaborating parties also included the group of Chris Dobson,
who was at that time leading the Oxford Center for Molecular
Sciences (OCMS). A few days after I came back from Japan, I
visited Chris together with André; from this first meeting, I
remember Chris’s enthusiasm for the project, his
great kindness and his humility.
During my 2 years in the group of André, we demonstrated
the high conformational stability of VHHs (Dumoulin et al.
2002). No need to mention that I particularly appreciated the
scientific environment of the CIP and the life in Liège since I
decided to finally settle down there! Toward the end of my
fellowship in Liège, I spent a few weeks in Oxford investigat-
ing how the binding of a VHH specific to human lysozyme
(HuL) can affect the behaviour of lysozyme natural variants
prone to forming amyloids. Within a few weeks, I collected a
large amount of data showing that the binding of the VHH to a
particular HuL amyloidogenic variant restores the
structural cooperativity characteristic of the wild-type protein.
These experiments benefitted from invaluable help provided
by the following people; Prof. Carol Robinson and her PhD
student, Alexander Last (analysis of H/D exchange profiles of
mutant and wildtype HuL in the presence/absence of
the VHH); Prof. Christina Redfield (mapping of the binding
site of the VHH on the surface of HuL by NMR); and Dr.
Denis Canet, a postdoctoral fellow in Chris group who first
described the loss of global cooperativity of the
amyloidogenic HuL variants (Canet et al. 2002). Up to that
point, these few weeks were the most intense and memorable
of my scientific life. Indeed, I will never forget the excitement
of everyone (especially Chris) and the numerous meetings we
had to discuss the results almost in real time. Back in Liège, I
conducted further experiments, utilizing the complementary
techniques of far UV-CD and tryptophan fluorescence, to fur-
ther characterize the stabilizing effects of the binding of the
VHH on the amyloidogenic variants of lysozyme. At the same
time, Aline Desmyter and Klass Decanniere from Lode’s lab-
oratory solved the X-ray structure of the complex formed be-
tween HuL and the antibody fragment; that data combined
with the NMR results allowed us to rationalize the effects of
the VHH. However, one crucial piece of information was
missing to make this into a great story: we did not know yet
if the binding of the VHH antibody fragment inhibited the
aggregation of the lysozyme variants into amyloid fibrils.
This turned out to be a very challenging problem to solve
experimentally since the VHH was not stable under the con-
ditions known to trigger, in vitro, the aggregation of HuL
variants into amyloid fibrils. To solve this problem, I moved
to England to work full-time in the Dobson group.
A research fellow at Oxford and then
Cambridge University
At the end of my fellowship in Liège, I joined Chris’s
group at Oxford in the spring of 2001, initially with
funding from a two-year Mary Curie Fellowship to work
on the VHH/lysozyme problem described above. I arrived
in Oxford just a few months before Chris moved to
Cambridge University as the newly appointed John
Humphrey Plummer Professor of Chemical and Structural
Biology. After joining his group, it took me a year and half
to find solution conditions where the variant lysozymes
could form amyloid fibrils but at which the VHH was still
functional and thus to be able to demonstrate the inhibitory
power of the VHH on fibril formation (Dumoulin et al.
2003). During this time, Chris’s attitude was very support-
ive, with a fine balance between gentle pressure, warm
encouragements and liberal dollops of good humour.
Chris had a unique ability to listen, motivate and encour-
age. I always felt enlightened, inspired and full of confi-
dence during and after meetings with him. I would like to
acknowledge the many valuable pieces of advice he gave
me during this time, such as the importance of persever-
ance, hard work and being always positive.
Chris’s interdepartmental appointment as a John
Humphrey Plummer Professor of Chemical and
Structural Biology was an opportunity for him to further
develop his multidisciplinary approach to tackling prob-
lems – a trademark style that he was passionate about. He
moved to Cambridge with a handful of postdoctoral fel-
lows including Jesus Zurdo, Cait MacPhee, Mark Krebs
and Michele Vendruscolo. We were quickly joined by
Natàlia Carullà, John Christodoulou and Goran Larsson
as new postdoctoral fellows and Caroline Wright and
Kristen Lindorff-Larsen as PhD students. It took us about
4 months to fully set up the laboratory in the basement of
the Department of Chemistry. When thinking back to this
period, it was a unique and funny experience. Although
Chris very rarely came down to the laboratory, he had a
very clear and precise vision of how things were and
should be going on there, especially with regard to the
problems and the solutions required to overcome them. I
remember one meeting that a few of us initiated, to dis-
cuss a list of issues related to the progress of installations
within the lab. As soon as we entered his office, Chris
very impressively went through all of our listed points
and quickly provided helpful ways to overcome these dif-
ficulties. It was as if he had seen our list in advance! Over
the next 2 years, we witnessed the arrival of nearly 50
talented PhD students and postdocs from all over the
world and from a variety of disciplines. Chris established
a unique intellectual and training environment that
was supportive, stimulating, extremely creative and
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sufficiently open-minded to allow each member to make
the best of him/herself. He especially provided a great
space for independent research by allowing each of us to
choose the direction of our own research according to our
specific interest while always providing illuminating guid-
ance and support. It was also at this time (2002) that Chris
started to work on proteins associated with neurodegener-
ative diseases, such as alpha-synuclein (Parkinson’s dis-
ease) and the Aβ-peptide (Alzheimer’s disease). Since
that time, his research has had a tremendous impact in
the field of medical research (Dobson 2017; Dobson
et al. 2019). In 2012, he founded the Cambridge Centre
for Misfolding Diseases which is currently based in the
Chemistry of Health building at the Department of
Chemistry at the University of Cambridge, and in 2016,
he co-founded Wren Therapeutics, a biotechnology start-
up company whose mission is to find new therapeutics for
Alzheimer’s disease. Chris received more than ninety ac-
ademic awards and honours including the Royal Medal by
the Royal Society “for his outstanding contributions to the
understanding of the mechanisms of protein folding and
misfolding, and the implications for disease” in 2009,
and in 2014, he received both the Heineken Prize for
Biochemistry and Biophysics and the Feltrinell i
International Prize for Medicine. Last but not least,
Chris was knighted in the 2018 Queen’s Birthday
Honours for his contributions to science and higher
education.
Altogether, I spent 7 years in Chris’ group (until
2008) including the last two 2 years during which I
shared my time between Cambridge and Liège, support-
ed by both Chris and a Belgian fellowship from the
FRS-FNRS. Chris trusted his co-workers to take charge
of projects and to work hard to make progress wherever
they worked. He was very flexible and provided free-
dom to people to organize their work in relation to their
personal situation, and he was a strong advocate of
women in science. I had the great privilege to continue
to work during these years investigating the mechanism
of fibril formation by the amyloidogenic variants iden-
tified from patients suffering from lysozyme amyloidosis
(Dumoulin et al. 2007). During this time, I had the
chance to interact with numerous collaborators both
within Chris’s group (and in particular with Dr. J. R.
Kumita) and also external to it. Lysozyme was a partic-
ularly special protein to Chris since he started working
on it during his PhD. More than 150 of the > 800 pa-
pers he published during his career deal with lysozyme
(mostly from either hen or human sources) including
four published in Nature and three published in
Science. I am proud to have contributed to this work
on lysozyme, having published 22 of these papers to-
gether with Chris.
A return to Belgium as permanent FRS-FNRS
research associate
In 2008, I received a research associate FRS-FNRS position at
the Centre of Protein Engineering (CIP) in the Department of
Life Sciences at the University of Liège where I am still hap-
pily working today. In the first years, my interest was essen-
tially focused on studying the aggregation properties of sev-
eral proteins, including a series of model polyQ proteins (e.g.
Scarafone et al. 2012; Huynen et al. 2015), as well as main-
taining a strong interest in VHHs and HuL. During this time, I
supervised five PhD students (Natacha Scarafone, Coralie
Pain, Janice Dumont, Chloé Chavignon and Céline Huynen)
and more than 25 Master students, including more than a
dozen from the University of Padova through exchanges with
Prof. Patrizia Polverino de Laureto to whom I was introduced
by Chris for collaborative projects on HuL nearly 20 years ago
(Frare et al. 2006). More recently, my research interests have
broadened to encompass the generation and use of VHHs to
tackle, via collaborative projects, a series of diseases. I am
coordinating the DiaSyn EuroNanomedII project aiming at
developing a PET imaging radiotracer for alpha-synuclein
(aSyn) detection and quantification in the brain. This project
involves: Dr.Mathieu Cinier (Affilogic, Nantes, France), Prof.
A. Luxen (GIGA-CRC, ULiège), Dr. Anne Michel (UCB-
Pharma, Braine l'Alleud, Belgium), Prof. Rosario Moratalla
(CAJAL Institute, Madrid, Spain) and Dr. Maxime Culot
(University of Artois, France). Moreover, in collaboration
with the group of Dr. Pierre Lafaye (Institut Pasteur, Paris)
and Prof. Alain Vanderplasschen (Fac. Veterinary Medicine,
ULiège) we are developping VHHs against specific aSyn
post-translational modifications as tools to better understand
the role of these later on the aggregation process of aSyn. The
second disease we are interested in is cystic fibrosis (CF). In
patients affected with CF, chronic respiratory infections lead
to the release of proteases whose actions contibute to the
destruction of the lung tissue. Within an Interuniversity pro-
ject leaded by Dr. Rita Vanbever (UCLouvain, Belgium) and
involving Prof. Teresinha Leal (UCLouvain) and Prof. S.
Muyldermans (VUB), we aim at developing a nanomedecine
inhibiting such enzymes for the treatment of the respiratory
pathology of CF. Moreover, in collaboration with Rita and
Serge, we are developing VHHs offering a sustained presence
of a drug protein within the lung to treat CF. We are also
involved into a project leaded by Dr. Jo Caers (GIGA3I,
UL i e g e ) a im i ng a t d ev e l o p i ng VHHs f o r t h e
immunotreatment of multiple myeloma. Last but not least,
we collaborate with the group of Prof. Moreno Galleni (CIP)
to generate VHHs inhibiting a series of enzymes involved in
antibiotic resistance, a research topic of particular importance
at CIP. My group is presently constituted by two talented
postdoctoral fellows, Dr. Rita Maalouf and Dr. Francisco
Morales, an invaluable technician Mr. Joël Moray, and three
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motivated Master students, Michele De Sabato, Paola
Redeghieri and Ludovica De Ceasaere.
After my departure from Cambridge, I continued to collab-
orate with Chris on the HuL topic. During that time, I regu-
larly visited his group collaborating with Dr. Janet Kumita, Dr.
Erwin de Genst, Dr. Xavier Salvatella and Dr. Alexander
Buell (e.g. Buell et al. 2011; Mossuto et al. 2011; Kumita
et al. 2012; Ahn et al. 2016). Moreover, for many years,
Chris had a special link with the University of Liège and
especially with André Matagne. Together with André and
Lode, he was involved in a Belgian Interuniversity
Attraction Poles (I.A.P., 2002–2007) during which the work
on VHHs directed toward alpha-synuclein was initiated (De
Genst et al. 2013). None of the work involving VHHs and
amyloid fibril formation would have been possible without
the close collaboration between the group of Chris, Lode
and André, and I am lucky to have been part of such a pro-
ductive network (Fig. 1). One of the lessons I learned from
Chris, was the importance of local and international collabo-
rations – advice that I am still following to this day (e.g.
Vandevenne et al. 2007, Gustot et al. 2013; Pansieri et al.
2017; Cawez et al. 2018). Chris visited the University of
Liège on many occasions. On two of these occasions (2005
& 2012), he gave a talk during the 1-day symposiums on
Protein Folding and Stability, organized annually by Prof.
André Matagne since 2002. In 2007, Chris received a
Honoris Causa degree from the University of Liège (Fig. 2).
At that occasion, he came along with his wife Mary, and we
spent a couple of great days with the two of them. I would like
to express my deep gratitude to Mary for all the kind attention
she paid to me while I was working at, or visiting, Cambridge.
Upon hearing the news of Chris’s death, I was touched by
several messages from people who had met him only once
while he was visiting Liège, expressing their sadness and ap-
preciation for Chris’s great scientific contribution as well as
his enormous kindness. This in itself provides a powerful tes-
timony to Chris’s uncanny ability to interact with people and
to touch them in a unique way.
Some final words of tribute to Professor Sir
Christopher M. Dobson
Over all of the years I spent in his laboratory (and even after
that), Chris taught me so many things that it is difficult to
report them all here. In particular, he taught me in many dif-
ferent ways how to become an independent researcher and
how to perform good science. These lessons have been ex-
tremely important in shaping my career. Chris had an excep-
tional talent in writing; his numerous corrections of my man-
uscripts provided a unique way to learn how to make the most
of data, how to put it in perspective and how to correctly frame
it within a larger context. Perhaps, most importantly, he taught
me, and many others, how to write a good paper. Chris gave
me the opportunity to actively participate in the writing of
Fig. 1 Professor Christopher Dobson with researchers involved in the
I.A.P network working on VHHs and amyloidogenic proteins at the
time of the 1-day symposiums on Protein Folding and Stability,
organized by Prof. André Matagne in 2005. From left to right: André
Matagne, Chris, Mireille Dumoulin, Jean-Marie Frère, Lode Wyns, Els
Pardon, Katja Conrath and Erwin De Genst
Fig. 2 Professor Christopher Dobson when he received his Honoris
Causa degree from the University of Liège in 2007
Biophys Rev (2020) 12:13–1816
grant applications which culminated in mymanagement of the
work package that Chris was in charge of within a large
European network project . When I obtained my position in
Liège, Chris worked for my inclusion in this network as an
independent PI; this is an example of his generosity and de-
votion to help establishing young researchers. This turned out
to be an extremely valuable learning experience for the future
of my career. It also gave me the opportunity to supervise
Masters and PhD students. His advice on how to perform
these duties remains invaluable to this very day.
Chris was a precious pillar of support and an incompa-
rable source of inspiration for all the scientists and students
he interacted with. He will be sorely missed, and his legacy
will live through the work of each of who had the chance to
work with him. Being mentored by such a great scientist
and a passionate man, committed in a unique way to the
people he worked with, has been one of my greatest priv-
ileges, and I will cherish every moment and discussion I
shared with him.
Thanks for all Chris! You will be for ever in my mind and
heart.
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